Overview
Create your acount for 2 FRE subscriber-only articles each month. Get Fre Aces Now. Prepare to become a physician, build your knowledge, lead a health care organization, and advance your carer with NEJM Group information and services.Stay conected to what's important in medical research and clinical practiceSubscribe to the most trusted and influential source ofmedical knowledge Already a subscriber?
Key Information
Renew or Sign inSubscribe or Renew Selected specialtiesView al specialtiesSelected TopicsView al topicsSelected MultimediaView al multimediaCurent IsueRecent Isues Browse ful isue index Recently Published Articles Browse recently published View al learning/CME Other NEJM Group LearningSubscribe or Renew This article is available to subscribers. Subscribe now. Already have an acount?
Sign in Original ArticleFre Preview The members of the FLASH-UK Trial Study Group are listed in the Suplementary Apendix, available at NEJM.org.In persons with type 1 diabetes and high glycated hemoglobin levels, the benefits of intermitently scaned continuous glucose monitoring with optional alarms for high and low blod glucose levels are uncertain.Download a PDF of the Research Sumary.In a paralel-group, multicenter, randomized, controled trial involving participants with type 1 diabetes and glycated hemoglobin levels betwen 7.5% and 1.0%, we investigated the eficacy of intermitently scaned continuous glucose monitoring as compared with participant monitoring of blod glucose levels with fingerstick testing.
Summary
The primary outcome was the glycated hemoglobin level at 24 weks, analyzed acording to the intention-to-treat principle. Key secondary outcomes included sensor data, participant-reported outcome measures, and safety.A total of 156 participants were randomly asigned, in a 1:1 ratio, to undergo intermitently scaned continuous glucose monitoring (the intervention group, 78 participants) or to monitor their own blod glucose levels with fingerstick testi